Lifeline Biotechnologies Total Debt vs. Current Ratio
| LLBO Stock | USD 0.0001 0.0003 75.00% |
For Lifeline Biotechnologies profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Lifeline Biotechnologies to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Lifeline Biotechnologies utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Lifeline Biotechnologies's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Lifeline Biotechnologies over time as well as its relative position and ranking within its peers.
Lifeline |
Lifeline Biotechnologies Current Ratio vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Lifeline Biotechnologies's current stock value. Our valuation model uses many indicators to compare Lifeline Biotechnologies value to that of its competitors to determine the firm's financial worth. Lifeline Biotechnologies is rated fourth overall in total debt category among its peers. It is currently regarded as number one stock in current ratio category among its peers . The ratio of Total Debt to Current Ratio for Lifeline Biotechnologies is about 53,215 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Lifeline Biotechnologies by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Lifeline Biotechnologies' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Lifeline Total Debt vs. Competition
Lifeline Biotechnologies is rated fourth overall in total debt category among its peers. Total debt of Medical Devices industry is now estimated at about 1.36 Billion. Lifeline Biotechnologies adds roughly 448,072 in total debt claiming only tiny portion of all equities under Medical Devices industry.
Lifeline Current Ratio vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Lifeline Biotechnologies |
| = | 448.07 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Lifeline Biotechnologies |
| = | 8.42 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Lifeline Current Ratio Comparison
Lifeline Biotechnologies is currently under evaluation in current ratio category among its peers.
Lifeline Biotechnologies Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Lifeline Biotechnologies, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Lifeline Biotechnologies will eventually generate negative long term returns. The profitability progress is the general direction of Lifeline Biotechnologies' change in net profit over the period of time. It can combine multiple indicators of Lifeline Biotechnologies, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Lifeline Biotechnologies, Inc. operates as a medical technology company in the United States. Lifeline Biotechnologies, Inc. is headquartered in Reno, Nevada. Lifeline Biotech operates under Medical Devices classification in the United States and is traded on OTC Exchange.
Lifeline Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Lifeline Biotechnologies. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Lifeline Biotechnologies position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Lifeline Biotechnologies' important profitability drivers and their relationship over time.
Use Lifeline Biotechnologies in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lifeline Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lifeline Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Lifeline Biotechnologies Pair Trading
Lifeline Biotechnologies Pair Trading Analysis
The ability to find closely correlated positions to Lifeline Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lifeline Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lifeline Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lifeline Biotechnologies to buy it.
The correlation of Lifeline Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lifeline Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lifeline Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lifeline Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Lifeline Biotechnologies position
In addition to having Lifeline Biotechnologies in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aggressive Defence Thematic Idea Now
Aggressive Defence
Macroaxis small cap, aggressive-outlook picks designed for investors that are willing to accept higher levels of risk to hedge exposure to above-average market volatility. The Aggressive Defence theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Defence Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Lifeline Pink Sheet
To fully project Lifeline Biotechnologies' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Lifeline Biotechnologies at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Lifeline Biotechnologies' income statement, its balance sheet, and the statement of cash flows.